DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/chwswq/pharmapoint) has announced the addition of the "PharmaPoint: Crohn's Disease - China Drug Forecast and Market Analysis to 2022" report to their offering.
The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge the current biologics in an attempt to dislodge the stronghold of the TNF inhibitors, as they aim to tap into the lucrative portion of the CD therapeutics market. If their promising safety and efficacy profiles translate to clinical practice once they enter the market, their launch will be to the detriment of the existing market leaders, Remicade (infliximab) and Humira (adalimumab).
The loss of patent protection of the anti-TNF marketed brands will allow for the emergence of biosimilars, such as Hospira's Inflectra (infliximab) a Remicade biosimilar. Focusing on country dynamics, Canada and the emerging markets of China and India will also play a key role in driving growth in the long term, with each market forecast to post positive Compound Annual Growth Rates (CAGRs) from 2012 to 2022, primarily due to the anticipated strong uptake of Remicade over the forecast period.
Based on Our primary research, the majority of Chinese gastroenterologists follow the ACG and/or the World Gastroenterology Organization (WGO) guidelines for the management of their CD patients. In a few cases, they also refer to the local treatment guidelines. Approximately 40% of the referrals for CD patients come from PCPs, while the rest arise from their colleagues or colorectal surgeons.
- Overview of Crohn's disease including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in China including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in China from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the China Crohn's disease market.
Key Topics Covered:
List of Tables
List of Figures
Opportunity and Unmet Need
For more information visit http://www.researchandmarkets.com/research/chwswq/pharmapoint
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.